Search research articles
Contact Us
Filters
Showing results (31-40 of 57) with videos related to
Page
of 6
Sort By:
The American Journal of Cardiology
|
July 5, 2005
Responsiveness of plasma lipids and lipoproteins to plant stanol esters
Nilo B Cater, Ana-Barbara Garcia-Garcia, Gloria Lena Vega, et al.
Clinical Pharmacology and Therapeutics
|
September 11, 2003
Free fatty acid metabolism during fenofibrate treatment of the metabolic syndrome
Gloria Lena Vega, Nilo B Cater, Dariusch R Hadizadeh, et al.
The American Journal of Cardiology
|
June 27, 2000
Incremental reduction of serum total cholesterol and low-density lipoprotein cholesterol with the addition of plant stanol ester-containing spread to statin therapy
S N Blair, D M Capuzzi, S O Gottlieb, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders
|
February 10, 2023
Efficacy and Safety of Ertugliflozin Added to Metformin: A Pooled Population from Asia with Type 2 Diabetes and Overweight or Obesity
Linong Ji, Jie Liu, Zhi Jin Xu, et al.
American Journal of Obstetrics & Gynecology MFM
|
September 5, 2021
Offering onsite COVID-19 vaccination to high-risk obstetrical patients: initial findings
Jonathan S Hirshberg, Bridget C Huysman, Megan C Oakes, et al.
The American Journal of Cardiology
|
April 11, 2003
Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome
Gloria Lena Vega, Patrick T S Ma, Nilo B Cater, et al.
Diabetes, Obesity & Metabolism
|
December 5, 2019
Efficacy and safety of ertugliflozin in East/Southeast Asian patients with type 2 diabetes mellitus
Jie Liu, Shrita Patel, Nilo B Cater, et al.
Annals of Medicine
|
January 23, 2009
Lipoprotein predictors of cardiovascular events in statin-treated patients with coronary heart disease. Insights from the Incremental Decrease In End-points Through Aggressive Lipid-lowering Trial (IDEAL)
Ingar Holme, Nilo B Cater, Ole Faergeman, et al.
The American Journal of Cardiology
|
July 21, 2010
Comparison of atorvastatin 80 mg/day versus simvastatin 20 to 40 mg/day on frequency of cardiovascular events late (five years) after acute myocardial infarction (from the Incremental Decrease in End Points through Aggressive Lipid Lowering [IDEAL] trial)
Terje R Pedersen, Nilo B Cater, Ole Faergeman, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
|
April 23, 2026
Association of Ertugliflozin on Kidney Outcomes in People After and Without an Interval Cardiovascular Event: Observations From the VERTIS CV Trial
Ayodele Odutayo, Francesco Cosentino, Richard E Pratley, et al.
Page
of 6
Search research articles
Search
Showing results (31-40 of 57) with videos related to
Sort By:
Page
of 6
The American Journal of Cardiology
|
July 5, 2005
Responsiveness of plasma lipids and lipoproteins to plant stanol esters
Nilo B Cater, Ana-Barbara Garcia-Garcia, Gloria Lena Vega, et al.
Clinical Pharmacology and Therapeutics
|
September 11, 2003
Free fatty acid metabolism during fenofibrate treatment of the metabolic syndrome
Gloria Lena Vega, Nilo B Cater, Dariusch R Hadizadeh, et al.
The American Journal of Cardiology
|
June 27, 2000
Incremental reduction of serum total cholesterol and low-density lipoprotein cholesterol with the addition of plant stanol ester-containing spread to statin therapy
S N Blair, D M Capuzzi, S O Gottlieb, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders
|
February 10, 2023
Efficacy and Safety of Ertugliflozin Added to Metformin: A Pooled Population from Asia with Type 2 Diabetes and Overweight or Obesity
Linong Ji, Jie Liu, Zhi Jin Xu, et al.
American Journal of Obstetrics & Gynecology MFM
|
September 5, 2021
Offering onsite COVID-19 vaccination to high-risk obstetrical patients: initial findings
Jonathan S Hirshberg, Bridget C Huysman, Megan C Oakes, et al.
The American Journal of Cardiology
|
April 11, 2003
Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome
Gloria Lena Vega, Patrick T S Ma, Nilo B Cater, et al.
Diabetes, Obesity & Metabolism
|
December 5, 2019
Efficacy and safety of ertugliflozin in East/Southeast Asian patients with type 2 diabetes mellitus
Jie Liu, Shrita Patel, Nilo B Cater, et al.
Annals of Medicine
|
January 23, 2009
Lipoprotein predictors of cardiovascular events in statin-treated patients with coronary heart disease. Insights from the Incremental Decrease In End-points Through Aggressive Lipid-lowering Trial (IDEAL)
Ingar Holme, Nilo B Cater, Ole Faergeman, et al.
The American Journal of Cardiology
|
July 21, 2010
Comparison of atorvastatin 80 mg/day versus simvastatin 20 to 40 mg/day on frequency of cardiovascular events late (five years) after acute myocardial infarction (from the Incremental Decrease in End Points through Aggressive Lipid Lowering [IDEAL] trial)
Terje R Pedersen, Nilo B Cater, Ole Faergeman, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
|
April 23, 2026
Association of Ertugliflozin on Kidney Outcomes in People After and Without an Interval Cardiovascular Event: Observations From the VERTIS CV Trial
Ayodele Odutayo, Francesco Cosentino, Richard E Pratley, et al.
Page
of 6